Evidence map›Paper›PMID 40524029›Full record

ArticleDiscover oncology2025

To reveal the key mechanism of Citri Reticulatae Pericarpium-Reynoutria japonica Houtt in the treatment of liver cancer and its correlation with lipid metabolism: synergetic effect with network pharmacology, molecular docking and bioinformatics.

Chen Lin, Yujie Wang, Xiao Lin, Chufan Ren, Yifeng Wang, Yizhong Ma, Jiahao Zhou, Chuyu Gu, Jianyi Wang

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Chen Lin *Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai, 200437, China.
Yujie Wang *Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai, 200437, China.
Xiao Lin *The First Affiliated Hospital, Wenzhou Medical University, Wenzhou, 325000, Zhejiang, China.
Chufan RenThe First School of Medicine, School of Information and Engineering, Wenzhou Medical University, Wenzhou, 325000, China.
Yifeng WangYueyang Hospital of Integrated Traditional Chinese and Western Medicine, Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai, 200437, China.
Yizhong MaYueyang Hospital of Integrated Traditional Chinese and Western Medicine, Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai, 200437, China.
Jiahao ZhouYueyang Hospital of Integrated Traditional Chinese and Western Medicine, Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai, 200437, China.
Chuyu GuZhejiang University of Finance & Economics Dongfang College, Haining, 314000, China.
Jianyi WangYueyang Hospital of Integrated Traditional Chinese and Western Medicine, Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai, 200437, China. wjydyj@163.com.

Funding

Shanghai Municipal Health Commission ZY(2018-2020)-RCPY-1011
6 · The paper itself

Abstract

backgroundLiver cancer (LC) is a prevalent malignancy characterized by insidious onset, high recurrence rates, and significant mortality. The herbal combination "Citri Reticulatae Pericarpium-Reynoutria japonica" (CR) has traditionally been used for managing LC and related disorders, demonstrating notable therapeutic efficacy. This study aims to identify the molecular targets of CR in LC and assess its pharmacological properties and potential toxicity.

methodsWe used GeneCards, OMIM, and TTD databases to identify targets associated with liver cancer and constructed protein-protein interaction (PPI) and herbal-target-pathway-disease interaction networks. We performed Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analyses to explore the molecular mechanisms of CR. We also used differential expression analysis with GEO datasets (GSE76427, GSE87630, and GSE112790) to validate liver cancer-related targets and identify common core targets.

resultsSurvival analysis indicated that HSP90AA1 may serve as a potential biomarker for LC. Molecular docking studies showed that rhein, a compound in CR, has a strong binding affinity to the identified target proteins. This research provides robust theoretical support for the clinical application of CR in treating LC, especially in cases related to non-alcoholic fatty liver disease (NAFLD) or Metabolic Lipid Disorders (DLM).

Indexed as

Citri Reticulatae Pericarpium-Reynoutria japonica HouttLipid metabolismLiver cancerMolecular dockingNetwork pharmacology

Identifiers

PMID40524029
PMCPMC12170481

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.